Oseltamivir phosphate is a prodrug that is converted after absorption into oseltamivir carboxylate, the active form of the drug. Oseltamivir carboxylate competitively inhibits influenza virus neuraminidase, an enzyme that is required for viral replication, release of virus from infected cells and the prevention of formation of viral aggregates after release from cells. Resistance to oseltamivir has been induced in the laboratory and from post-treatment isolates from infected humans. Oseltamivir or oseltamivir carboxylate do not act as substrates or inhibitors for any CYP-450 isoenzymes. It has been postulated that oseltamivir may limit the ability of canine parvovirus to pass through intestinal mucosa and infect intestinal crypt cells. There is evidence that oseltamivir has this effect (increased mucous inactivation) on influenza viruses in the respiratory tract of humans. Additionally, it may reduce GI bacteria colonization, translocation and toxin production.
The veterinary use of these agents has been primarily in the treatment of bone, skin, and other soft tissue infections in small animals when penicillinase-producing Staphylococcus species have been isolated. Because of its rapid elimination and required frequent dosing, it is infrequently used.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認實際物種、疾病與診斷 確認實際產品、鹽型、劑型與含量表達 由主治獸醫師依個案判斷風險、監測與合法性
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
6-10 hours
fecal